{"organizations": [], "uuid": "83bb7e7b43708b8f6d8c7b58ac8bd7df8654a096", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180425.html", "section_title": "Archive News &amp; Video for Wednesday, 25 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-bone-therapeutics-fy-net-loss-down/brief-bone-therapeutics-fy-net-loss-down-at-12-8-million-euros-idUSFWN1S11DQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Bone Therapeutics FY Net Loss Down At 12.8 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.712, "site_type": "news", "published": "2018-04-25T13:14:00.000+03:00", "replies_count": 0, "uuid": "83bb7e7b43708b8f6d8c7b58ac8bd7df8654a096"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-bone-therapeutics-fy-net-loss-down/brief-bone-therapeutics-fy-net-loss-down-at-12-8-million-euros-idUSFWN1S11DQ", "ord_in_thread": 0, "title": "BRIEF-Bone Therapeutics FY Net Loss Down At 12.8 Million Euros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ayed union", "sentiment": "none"}, {"name": "asahi kasei", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - BONE THERAPEUTICS SA:\n* STRONG CLINICAL PROGRESS IN ALLOB SPINAL FUSION AND DELAYED UNION TRIALS\n* LEADERSHIP TEAM STRENGTHENED WITH APPOINTMENTS OF JEAN STÉPHENNE AS CHAIRMAN OF THE BOARD (POST PERIOD) AND JEAN-LUC VANDEBROEK AS CFO\n* FY NET LOSS OF EUR 12.8 MILLION VERSUS LOSS OF EUR 13.0 MILLION YEAR AGO\n* EXCLUSIVE LICENSING AGREEMENT SIGNED WITH ASAHI KASEI FOR DEVELOPMENT AND COMMERCIALIZATION OF PREOB IN JAPAN\n* FY OPERATING LOSS EUR 12.3 MILLION VERSUS LOSS OF EUR 12.8 MILLION YEAR AGO\n* € 19.45 MILLION OF COMMITMENT SECURED FOLLOWING PRIVATE PLACEMENT OF CONVERTIBLE BONDS (POST PERIOD)\n* CASH AT END OF Q4 EUR 8.41 MILLION VERSUS EUR 20.3 MILLION YEAR AGO\n* BONE THERAPEUTICS PLANS TO REPORT THE FINAL RESULTS FROM THE ALLOB® PHASE I/IIA DELAYED-UNION STUDY IN MID-2018.\n* A VALUE INFLECTION POINT IS ANTICIPATED IN THE SECOND HALF OF 2018,\n* CASH BURN FOR THE FULL YEAR OF 2018 IS EXPECTED TO BE IN THE RANGE OF € 15-16 MILLION\n* CO WILL HAVE SUFFICIENT CASH TO CARRY OUT ITS OBJECTIVES UNTIL END Q3 2019\n* CASH AT END OF Q4 EUR 8.41 MILLION VERSUS EUR 20.3 MILLION YEAR AGO Source text : bit.ly/2qVTnTP Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://bit.ly/2qVTnTP", "https://instagram.com/reuters/"], "published": "2018-04-25T13:14:00.000+03:00", "crawled": "2018-04-26T20:10:47.036+03:00", "highlightTitle": ""}